智通财经网·2026-01-15 08:35Core Viewpoint - CICC maintains a target price of HKD 8.9 for China Biologic Products (01177) and a "outperform industry" rating, with adjusted net profit forecasts for 2025 and 2026 remaining at RMB 4.47 billion and RMB 4.92 billion respectively, and introducing a forecast of RMB 5.42 billion for 2027 [1] Group 1 - The company announced a 100% acquisition of Hejia Bio for RMB 1.2 billion [1] - Hejia Bio focuses on the siRNA sector, particularly in the areas of weight loss metabolism, cardiovascular, and neurological diseases, with a core platform that has competitive advantages [1] - The existing therapies in the chronic disease field generally have limitations in efficacy, safety risks, and low patient compliance, indicating a significant unmet clinical need [1] Group 2 - The acquisition is expected to help China Biologic Products build a next-generation cardiovascular treatment innovation pipeline and enhance its layout in the weight loss metabolism field [1] - The company's established R&D system and sales channels are likely to facilitate the efficient clinical advancement and subsequent commercialization of Hejia Bio's products, leading to potential synergistic benefits for both parties [1]